DADC
ACAD icon

D.A. Davidson & Co’s Acadia Pharmaceuticals ACAD Stock Holding History

D.A. Davidson & Co’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-19,549
Closed -$406K – 1091
2018
Q3 		$406K Sell
19,549
-13,300
-40% -$209K 0.01% 792
2018
Q2 		$502K Buy
32,849
+3,150
+11% +$56.2K 0.01% 700
2018
Q1 		$667K Buy
29,699
+100
+0.3% +$2.77K 0.01% 595
2017
Q4 		$891K Buy
29,599
+1,508
+5% +$48.2K 0.02% 491
2017
Q3 		$1.06M Buy
28,091
+900
+3% +$29.3K 0.02% 493
2017
Q2 		$758K Sell
27,191
-1,900
-7% -$56.6K 0.02% 513
2017
Q1 		$1M Buy
29,091
+641
+2% +$22.6K 0.02% 442
2016
Q4 		$820K Buy
+28,450
New +$753K 0.02% 511
2016
Q3 		– Sell
-500
Closed -$16K – 2366
2016
Q2 		$16K Hold
500
– – ﹤0.01% 1821
2016
Q1 		$13K Buy
+500
New +$10.9K ﹤0.01% 1833

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

D.A. Davidson & Co's ACAD Position: Q4 2018 in Review

D.A. Davidson & Co sold out of Acadia Pharmaceuticals (ACAD) in Q4 2018, closing a stake of 19,549 shares — an estimated $406K sold.

D.A. Davidson & Co first reported a position in ACAD in Q1 2016 and held it in 10 quarters. The position peaked at $1.06M in Q3 2017. 186 funds tracked by Wall St. Rank hold ACAD as of Q4 2018.

  • D.A. Davidson & Co reported no remaining Acadia Pharmaceuticals position as of Q4 2018 after selling out during the quarter.
  • D.A. Davidson & Co sold 19,549 Acadia Pharmaceuticals shares in Q4 2018, an estimated $406K.
  • D.A. Davidson & Co first reported a position in Acadia Pharmaceuticals in Q1 2016 and held it in 10 quarters.
  • D.A. Davidson & Co's Acadia Pharmaceuticals position peaked at $1.06M in Q3 2017.
  • 186 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q4 2018.

Based on D.A. Davidson & Co's 13F filing for Q4 2018, filed 29 Jan 2019.